Skip to the main content.
Contact Us

At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.

1 min read

Fluxion announced the use of its IonFlux automated patch clamp system in a successful drug discovery workflow targeting modulation of glycine receptors

August 3 2016

South San Francisco, Calif. – Fluxion Biosciences announced the release of a user publication demonstrating the efficacy of the IonFlux HT automated patch clamp system as a key component of the drug discovery process. Neusentis (Pfizer Ltd.) published a study investigating the effectiveness of discovering positive allosteric modulators (PAMs) of glycine receptors.  The publication highlighted the use of a discovery workflow using a fluorescent membrane potential primary screen, followed by the IonFlux HT for the secondary screening and biophysical characterization. The screening campaign successfully  qualified several compounds as PAMs for glycine receptors.

Glycine receptors are highly expressed in the dorsal horn of the spinal cord and can play an important role in dampening neurotransmission. This study established a screening workflow to identify new drugs for potentiating glycine receptors with the aim of developing higher potency compounds suitable for pain and analgesic medicine.

With its highly flexible fluidics system, IonFlux provide continuous flow and rapid, consistent liquid exchange.  IonFlux is ideal for medium-to-high throughput investigation of complex ligand-gated receptors. The system’s assay stability, coupled with unique experimental protocols, provides the most consistent platform for PAM investigations. Using IonFlux HT as the second step in their screening workflow, the investigators qualified and decreased the number of false positives seen with the fluorescent assay. From the authors: “… despite the high rate of false positives, through use of the medium-throughput IonFlux HT assay, we were able to rapidly identify genuine PAMs with an excellent translation to manual patch clamp”. 

Identification of Positive Allosteric Modulators of Glycine Receptors from a High-Throughput Screen Using a Fluorescent Membrane Potential Assay
C Stead et al,  J Biomol Screen. 2016 Jul 7

IonFlux systems and consumables are sold and supported internationally by Fluxion Biosciences. For further information, contact:

Ali Yehia, PhD
VP IonFlux

About Fluxion Biosciences
Fluxion Biosciences manufactures the IonFlux™ automated patch clamp system for ion channel drug discovery. The system deploys a unique in-plate cell attachment, recording and drug delivery system that provides rapid parallel recordings for ligand- and voltage-gated channels and facilitates complicated drug screening assays.  Premier institutions globally use Fluxion’s pioneering platforms, including the IsoFlux liquid biopsy system and the BioFlux cell analysis system in various disease research areas, including cancer, microbiology, and immunology.